Biblio
“The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
, “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “Cognitive reserve in ageing and Alzheimer's disease.”, Lancet Neurol, vol. 11, no. 11, pp. 1006-12, 2012.
, “Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1115-22, 2016.
, “Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.”, J Alzheimers Dis, vol. 50, no. 1, pp. 271-82, 2016.
, “Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice.”, Nat Med, vol. 20, no. 6, pp. 659-63, 2014.
, “REST and stress resistance in ageing and Alzheimer's disease.”, Nature, vol. 507, no. 7493, pp. 448-54, 2014.
, “Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”, J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
, “A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.”, Nature, vol. 488, no. 7409, pp. 96-9, 2012.
, “Neuronal basis of age-related working memory decline.”, Nature, vol. 476, no. 7359, pp. 210-3, 2011.
, “Exercise training increases size of hippocampus and improves memory.”, Proc Natl Acad Sci U S A, vol. 108, no. 7, pp. 3017-22, 2011.
, “Characterization of Amyloid-β Deposits in Bovine Brains.”, J Alzheimers Dis, vol. 51, no. 3, pp. 875-87, 2016.
, “Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 51, no. 3, pp. 867-73, 2016.
, “The Role of Alzheimer's and Cerebrovascular Pathology in Mediating the Effects of Age, Race, and Apolipoprotein E Genotype on Dementia Severity in Pathologically-Confirmed Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 531-45, 2016.
, “White Matter Changes are Associated with Ventricular Expansion in Aging, Mild Cognitive Impairment, and Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 329-42, 2016.
, “Strategies for improving memory: a randomized trial of memory groups for older people, including those with mild cognitive impairment.”, J Alzheimers Dis, vol. 49, no. 1, pp. 31-43, 2016.
, “Age and its association with low insulin and high amyloid-β peptides in blood.”, J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
, “Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).”, J Alzheimers Dis, vol. 49, no. 2, pp. 287-300, 2016.
, “The Korean Size/Weight Attribute Test: A Semantic Knowledge Test for Korean Older Adults and Brain-Imaging Evidence.”, J Alzheimers Dis, vol. 49, no. 2, pp. 377-86, 2016.
, “Sensitivity of Neuropsychological Tests to Identify Cognitive Decline in Highly Educated Elderly Individuals: 12 Months Follow up.”, J Alzheimers Dis, vol. 49, no. 3, pp. 607-16, 2016.
, “Mild Cognitive Impairment and Susceptibility to Scams in Old Age.”, J Alzheimers Dis, vol. 49, no. 3, pp. 845-51, 2016.
, “Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid.”, J Alzheimers Dis, vol. 49, no. 3, pp. 829-44, 2016.
, “Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1169-77, 2016.
, “Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.”, J Alzheimers Dis, vol. 50, no. 1, pp. 111-26, 2016.
, “A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.”, J Alzheimers Dis, vol. 50, no. 1, pp. 201-15, 2016.
,